patients with solid tumors, especially women with ovarian carcinoma. 20 This possibility should also be considered when interpreting a germline result, especially when the allelic fraction of a mutation is <50%. We have shown that the TP53 mutation
Search Results
Rachel L. Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, and Lydia Usha
Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya, and George Ansstas
of cases, 2 – 4 their reported frequency in adult HGGs (1%–3%) 5 – 8 is comparable to that of other solid tumor types, such as colorectal carcinoma (3%), 9 NSCLC (3%), 10 ovarian carcinoma (0.5%), 11 and squamous cell carcinoma of the head and
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh
versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern
Antoni Ribas
activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients . Proc Natl Acad Sci U S A 2003 ; 100 : 4712 – 4717 . 63. Phan GQ Yang JC Sherry RM . Cancer
Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong
; 11 : 172 – 179 . 28 Numnum TM Kimball KJ Rocconi RP . Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024
David M. O’Malley
, . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial . Lancet 2017 ; 390 : 1949 – 1961 . 10.1016/S0140-6736(17)32440-6 28916367
recommendations,” said Dr. Morgan. The NCCN Guidelines continue to recommend that women with borderline epithelial ovarian cancer of low malignant potential be primarily surgically managed. In contrast to patients with frankly invasive ovarian carcinoma, women
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
. 13. Morgan JS Adams M Mason MD . Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma . Eur J Cancer 1994 ; 30A : 1205 – 1206 . 14. Navo M Kunthur A Badell ML . Evaluation of the incidence of
Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer
former population. 55 , 57 , 69 – 72 Mutations are also associated with nonmucinous ovarian carcinoma as opposed to mucinous. 56 , 58 Mucinous epithelial ovarian carcinomas may be associated with other gene mutations, such as TP53 mutations, 73 which
Saranya Chumsri, Jodi Weidler, Siraj Ali, Sohail Balasubramanian, Gerald Wallweber, Lisa DeFazio-Eli, Ahmed Chenna, Weidong Huang, Angela DeRidder, Lindsay Goicocheal, and Edith A. Perez
extracellular domain mutations of ERBB2 . Proc Natl Acad Sci U S A 2012 ; 109 : 14476 – 14481 . 27. Cancer Genome Atlas Research Network . Integrated genomic analyses of ovarian carcinoma . Nature 2011 ; 474 : 609 – 615 . 28
